ID   SK-MEL-29.1.22
AC   CVCL_D3EZ
DR   Wikidata; Q127384301
RX   PubMed=9605759;
CC   Population: Caucasian.
CC   HLA typing: A*28; B*44,w45; C*w5,w6 (PubMed=9605759).
CC   Sequence variation: Gene deletion; HGNC; HGNC:4931; HLA-A; Zygosity=Heterozygous (PubMed=9605759).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Axillary lymph node; UBERON=UBERON_0001097.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_IY54 ! SK-MEL-29.1
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 30-01-24; Last updated: 19-12-24; Version: 3
//
RX   PubMed=9605759;
RA   Wang Z.-G., Seliger B., Mike N., Momburg F., Knuth A., Ferrone S.;
RT   "Molecular analysis of the HLA-A2 antigen loss by melanoma cells
RT   SK-MEL-29.1.22 and SK-MEL-29.1.29.";
RL   Cancer Res. 58:2149-2157(1998).
//